WO2012111996A3 - 갈란타민 또는 그의 염을 함유하는 경피흡수제제 - Google Patents

갈란타민 또는 그의 염을 함유하는 경피흡수제제 Download PDF

Info

Publication number
WO2012111996A3
WO2012111996A3 PCT/KR2012/001186 KR2012001186W WO2012111996A3 WO 2012111996 A3 WO2012111996 A3 WO 2012111996A3 KR 2012001186 W KR2012001186 W KR 2012001186W WO 2012111996 A3 WO2012111996 A3 WO 2012111996A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery system
transdermal delivery
salts
system containing
styrene
Prior art date
Application number
PCT/KR2012/001186
Other languages
English (en)
French (fr)
Other versions
WO2012111996A2 (ko
Inventor
최후균
전명관
Original Assignee
조선대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조선대학교산학협력단 filed Critical 조선대학교산학협력단
Priority to JP2013554396A priority Critical patent/JP5883459B2/ja
Priority to US13/985,994 priority patent/US20130324950A1/en
Priority to AU2012218255A priority patent/AU2012218255B2/en
Priority to CA2827470A priority patent/CA2827470A1/en
Priority to EP12746904.7A priority patent/EP2676663B1/en
Priority to CN201280009262.3A priority patent/CN103429233B/zh
Publication of WO2012111996A2 publication Critical patent/WO2012111996A2/ko
Publication of WO2012111996A3 publication Critical patent/WO2012111996A3/ko
Priority to HK14101466.7A priority patent/HK1189156A1/zh
Priority to US15/215,302 priority patent/US10758546B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 유효성분으로서 갈란타민 또는 그의 약학적으로 허용가능한 염; 점착제로서 스티렌-부타디엔-스티렌 공중합체 또는 스티렌-이소프렌-스티렌 공중합체를 포함하는 약물-함유 매트릭스층을 포함하는 경피흡수제제를 제공한다.
PCT/KR2012/001186 2011-02-18 2012-02-17 갈란타민 또는 그의 염을 함유하는 경피흡수제제 WO2012111996A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2013554396A JP5883459B2 (ja) 2011-02-18 2012-02-17 ガランタミンまたはその塩を含む経皮送達システム
US13/985,994 US20130324950A1 (en) 2011-02-18 2012-02-17 Transdermal delivery system containing galantamine or salts thereof
AU2012218255A AU2012218255B2 (en) 2011-02-18 2012-02-17 Transdermal delivery system containing galantamine or salts thereof
CA2827470A CA2827470A1 (en) 2011-02-18 2012-02-17 Transdermal delivery system containing galantamine or salts thereof
EP12746904.7A EP2676663B1 (en) 2011-02-18 2012-02-17 Transdermal delivery system containing galantamine or salts thereof
CN201280009262.3A CN103429233B (zh) 2011-02-18 2012-02-17 含有加兰他敏或其盐的经皮输送系统
HK14101466.7A HK1189156A1 (zh) 2011-02-18 2014-02-14 含有加蘭他敏或其鹽的經皮輸送系統
US15/215,302 US10758546B2 (en) 2011-02-18 2016-07-20 Transdermal delivery system containing galantamine or salts thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0014530 2011-02-18
KR1020110014530A KR101317158B1 (ko) 2011-02-18 2011-02-18 갈란타민 또는 그의 염을 함유하는 경피흡수제제

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/985,994 A-371-Of-International US20130324950A1 (en) 2011-02-18 2012-02-17 Transdermal delivery system containing galantamine or salts thereof
US15/215,302 Continuation US10758546B2 (en) 2011-02-18 2016-07-20 Transdermal delivery system containing galantamine or salts thereof

Publications (2)

Publication Number Publication Date
WO2012111996A2 WO2012111996A2 (ko) 2012-08-23
WO2012111996A3 true WO2012111996A3 (ko) 2012-10-26

Family

ID=46673057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001186 WO2012111996A2 (ko) 2011-02-18 2012-02-17 갈란타민 또는 그의 염을 함유하는 경피흡수제제

Country Status (10)

Country Link
US (2) US20130324950A1 (ko)
EP (1) EP2676663B1 (ko)
JP (1) JP5883459B2 (ko)
KR (1) KR101317158B1 (ko)
CN (1) CN103429233B (ko)
AU (1) AU2012218255B2 (ko)
CA (1) CA2827470A1 (ko)
HK (1) HK1189156A1 (ko)
MY (1) MY166972A (ko)
WO (1) WO2012111996A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317158B1 (ko) 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
CN106265678B (zh) * 2016-07-18 2019-06-04 陕西省中医医院 一种用于治疗面瘫的膏药及其制备方法
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089267A (en) * 1988-12-22 1992-02-18 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutical system comprising physostigmine as active component and process for the production thereof
US5700480A (en) * 1993-01-23 1997-12-23 Lts Lohman Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising galanthamine as active component
US5932238A (en) * 1990-03-29 1999-08-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Galanthamine containing transdermal applicator for the treatment of alcoholism
US6558696B1 (en) * 1999-02-19 2003-05-06 Lts Lohmann Therapie Systeme Ag Desoxypeganine
WO2007064407A1 (en) * 2005-12-01 2007-06-07 Novartis Ag Transdermal therapeutic system

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19527925C2 (de) * 1995-07-29 1997-07-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer trennmittelbeschichteten Schutzschicht
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2003032960A1 (fr) * 2001-10-17 2003-04-24 Hisamitsu Pharmaceutical Co., Inc. Preparations pour absorption percutanee
WO2006124584A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
TWI261378B (en) 2005-09-19 2006-09-01 Ind Tech Res Inst Polarized light emitting device
US20070104771A1 (en) 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
US8383149B2 (en) 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
WO2007129427A1 (ja) * 2006-05-08 2007-11-15 Teikoku Seiyaku Co., Ltd. 抗認知症薬物の経皮吸収製剤
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
KR20120101704A (ko) * 2009-12-16 2012-09-14 고토 다케시 항인지증 약물의 경피흡수제제
NZ605352A (en) 2010-06-30 2013-10-25 Nal Pharmaceuticals Ltd Process for producing glycosaminoglycans
KR101317158B1 (ko) 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089267A (en) * 1988-12-22 1992-02-18 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutical system comprising physostigmine as active component and process for the production thereof
US5932238A (en) * 1990-03-29 1999-08-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Galanthamine containing transdermal applicator for the treatment of alcoholism
US5700480A (en) * 1993-01-23 1997-12-23 Lts Lohman Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising galanthamine as active component
US6558696B1 (en) * 1999-02-19 2003-05-06 Lts Lohmann Therapie Systeme Ag Desoxypeganine
WO2007064407A1 (en) * 2005-12-01 2007-06-07 Novartis Ag Transdermal therapeutic system

Also Published As

Publication number Publication date
JP5883459B2 (ja) 2016-03-15
EP2676663A4 (en) 2015-06-03
AU2012218255A1 (en) 2013-09-12
AU2012218255B2 (en) 2017-01-19
CA2827470A1 (en) 2012-08-23
US20160339038A1 (en) 2016-11-24
JP2014505724A (ja) 2014-03-06
CN103429233B (zh) 2016-03-02
EP2676663B1 (en) 2018-05-23
US20130324950A1 (en) 2013-12-05
WO2012111996A2 (ko) 2012-08-23
CN103429233A (zh) 2013-12-04
KR20120106906A (ko) 2012-09-27
KR101317158B1 (ko) 2013-10-15
EP2676663A2 (en) 2013-12-25
HK1189156A1 (zh) 2014-05-30
US10758546B2 (en) 2020-09-01
MY166972A (en) 2018-07-27

Similar Documents

Publication Publication Date Title
WO2012002640A3 (ko) 도네페질을 함유하는 경피흡수제제
WO2011029948A3 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon
MX366230B (es) Composiciones multipolimericas para liberación transdermica de farmaco.
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
WO2012034079A3 (en) Macrolide dosage forms
WO2010042471A3 (en) Medical devices for delivery of therapeutic agents to body lumens
WO2011076621A3 (de) Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
MY183873A (en) Transdermal therapeutic system for application of an agent
MX2012008381A (es) Tira dental para administracion de tratamiento oral.
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
WO2012158030A3 (en) Drug delivery system
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
WO2012097264A3 (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2012172433A3 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
MY162768A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
ZA200904563B (en) Transdermal Therapeutic system for administering water-soluble active ingredients
TN2011000352A1 (en) New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
LT2009004A (en) New combination of active ingredients containing a non steroidal antiimplamatotory drug and a colchicoside derivative
EA201992463A1 (ru) Система доставки лекарственного средства

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12746904

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2827470

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013554396

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13985994

Country of ref document: US

Ref document number: 2012746904

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012218255

Country of ref document: AU

Date of ref document: 20120217

Kind code of ref document: A